But does show that a large pharma can use it's funding and distribution muscle, to great advantage against a relatively small competitor.
Makes you ponder the benefit a large pharma partner could be to PRR, once further positive test results come in for CVac (i.e post significant sp accretion for existing holders).
Add to My Watchlist
What is My Watchlist?
